Himanshu Sehgal’s Post

The #biotechnology and #pharmaceutical sectors are witnessing groundbreaking advancements that promise to reshape the industry landscape. Here are some of the most notable developments: 📊 Key Highlights: 1️⃣ Roche’s Ambitious Plans: Roche plans to launch 20 new medicines by the end of the decade and cut research costs by 20%. Focus areas include oncology, neurology, cardiovascular-metabolic diseases, eye diseases, and immune diseases. This strategy aims to boost the success rate of late-stage trials and streamline R&D processes. 2️⃣ AstraZeneca’s Strategic Partnership: AstraZeneca has entered a $1.92 billion license agreement with CSPC Pharmaceutical Group to develop a novel small molecule Lipoprotein (a) disruptor. This collaboration aims to address high cholesterol levels and enhance cardiovascular health. 3️⃣ Boehringer Ingelheim’s New Research Facility: Boehringer Ingelheim has opened a €60 million research building in Vienna, dedicated to oncology therapeutics. This facility is part of a broader $7.8 billion investment plan, highlighting the company’s commitment to cancer research and sustainability. 💡 Takeaway: The biotechnology and pharmaceutical sectors are on the cusp of transformative growth. Strategic investments, innovative technologies, and regulatory advancements are driving the industry forward. Embracing these changes will be crucial for success in 2025 and beyond. Mohammad Hassan Khalid, Pernilla Isberg, Irena Brookes-Smith, Jochen Hurlebaus, Okan Ekinci, MD MBA, Gian Luca Satti, Michael Schorpp, Dr. Michael Kurr, Elizabeth A. 📖 Explore the full articles for detailed information 👇 #lifescience #phartmatech #biotech #ai #data #research #development #cloud

📢📄 [#PressRelease] Lys Therapeutics secures an additional €2.15 million in #funding as a winner of the i-Nov innovation competition organized by the French government to accelerate the clinical development of its drug candidate #LYS241. Lyon & Caen, France, September 24, 2024 – Lys Therapeutics, a pioneering French biotechnology company revolutionizing the treatment of patients suffering from neurodegenerative or neurovascular diseases, today announces that it has secured €2.15 million in funding from France 2030 as a laureate of the 12th edition of the French Government i-Nov innovation competition, led by the General Secretariat for Investment (SGPI) and operated by Bpifrance. Lys Therapeutics has received the largest amount of funding among the winners of this edition of the competition. More information on https://lnkd.in/eJJdFrp2 --- With Bruno Bonnell, Nicolas Dufourcq & Lise ALTER Bpifrance, Secrétariat général pour l'investissement, Agence de l'innovation en santé, Ministère de l’Économie, des Finances et de la Souveraineté industrielle et numérique, Ministère de l'Enseignement supérieur et de la Recherche, Ministère de la Santé, Direction générale de la recherche et de l'innovation (DGRI)

🎉 Big News in Biotech! 🧬 Pfizer, a global pharmaceutical leader, has just inked a monumental 15-year lease for their oncology division in San Diego, marking the region's largest biotech transaction in over a year. This move into the Torrey View office and lab campus by Pfizer emphasizes the ongoing expansion and innovation in cancer therapy research. 🏢💡 As part of Breakthrough Properties’ development, this 230,000-square-foot lease brings the campus to full occupancy before its completion, showcasing the vibrant future of biotech in San Diego, the nation's third-largest biotech hub. 🌟 This lease symbolizes a significant boost in the biotech sector, amidst a time when life science deals are seeking momentum. It reflects the industry's shift towards major research and development efforts in areas like cancer, diabetes, and more. 📈🔬 San Diego continues to attract global pharmaceutical giants, fostering advancements and potentially life-saving therapies. Let's celebrate this leap forward in biotech innovation and the promising developments it heralds for healthcare. 🎗️ For more details on this, check out the full article here: https://lnkd.in/gQMqwkTe (Note: Article is behind a Members only login). . . . . #AJGeorgeResimercial #CommercialRealEstateSanDiego #ResimercialRealEstate #ResimercialRealtor #RealEstateTransactions #Biotech #Pfizer #HealthcareIndusty #HealthcareInnovation #SanDiegoBiotech

#News: #Blockbuster #weightloss #drugmaker Novo Nordisk (NOVOb.CO) announced on Thursday research collaborations with two U.S. #biotech firms, part of its efforts to stay ahead in #bigpharma's race to develop more treatments for #cardiometabolic diseases. Novo, a Danish drugmaker whose share price rose 49% last year due to soaring demand for its weight-loss medicine #Wegovy, said the partnerships with Omega Therapeutics (OMGA.O) and Cellarity Inc could lead to new treatments for people living with obesity and a type of liver disease known as #MASH. Shares of Cambridge, Massachusetts-based #Omega, which had a market capitalization of about $150 million as of Wednesday's close, nearly doubled to $5.38 in U.S. premarket trading. The two separate research and development collaborations are the first announced under a framework deal that Novo signed in 2022 with Flagship Pioneering, a U.S. investment firm focused on #lifesciences. #Omega and #Cellarity are both portfolio companies of #Flagship. The companies will jointly conduct pre-clinical trial drug development work with Novo. After that, Novo could advance the programmes into clinical studies, it said in a statement. Read more from Reuters 👇

TLDR Biotech for June 26 - 27 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Novo Nordisk buys 2seventy bio’s Hemophilia A asset for $40M 🤝 + 1 more story 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: Silence Therapeutics reports encouraging early Ph1 blood disorder data 🩸 + 2 more stories 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: WayPoint Bio launches to "test hundreds [of cell therapies] at once" 🤯 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Holoclara’s worm-derived therapies raise a $16M Series A 🪱 + 5 more stories 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬: Vigil Therapeutics receive $40M strategic investment from Sanofi 💼 𝐌𝐞𝐫𝐠𝐞𝐫𝐬 & 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬: AbbVie brings the heat, buys Celsius Therapeutics for $250M cash 🔥 + 3 more stories 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Kite Pharma signs on to assess Cellares’ cell therapy manufacturing platform 🤖 𝐏𝐨𝐥𝐢𝐭𝐢𝐜𝐬 & 𝐏𝐨𝐥𝐢𝐜𝐲: Medicare inches closer to covering weight loss drugs 💊 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: Eisai, Biogen's Leqembi launches in China 🚀 All this and more in today's TLDR Biotech newsletter - link to the latest issue: https://lnkd.in/gT9Z6KEQ Or subscribe to get it straight to your inbox: https://lnkd.in/gecXctqM #tldrbiotech #biotechnews #pharmanews

TLDR Biotech for June 26 - 27 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Novo Nordisk buys 2seventy bio’s Hemophilia A asset for $40M 🤝 + 1 more story 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: Silence Therapeutics reports encouraging early Ph1 blood disorder data 🩸 + 2 more stories 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: WayPoint Bio launches to "test hundreds [of cell therapies] at once" 🤯 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Holoclara’s worm-derived therapies raise a $16M Series A 🪱 + 5 more stories 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭𝐬: Vigil Therapeutics receive $40M strategic investment from Sanofi 💼 𝐌𝐞𝐫𝐠𝐞𝐫𝐬 & 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬: AbbVie brings the heat, buys Celsius Therapeutics for $250M cash 🔥 + 3 more stories 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Kite Pharma signs on to assess Cellares’ cell therapy manufacturing platform 🤖 𝐏𝐨𝐥𝐢𝐭𝐢𝐜𝐬 & 𝐏𝐨𝐥𝐢𝐜𝐲: Medicare inches closer to covering weight loss drugs 💊 𝐏𝐫𝐨𝐝𝐮𝐜𝐭 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: Eisai, Biogen's Leqembi launches in China 🚀 All this and more in today's TLDR Biotech newsletter - link to the latest issue: https://lnkd.in/gfw7pkVK Or subscribe to get it straight to your inbox: https://lnkd.in/gh68uhTQ #tldrbiotech #biotechnews #pharmanews

🚀 The growing importance of health-related sectors is underscored by the GPW Benchmark's decision to begin publishing a new cross-sector index, WIGmed, starting June 24, 2024, which brings together companies in the medical industry, including hospitals, drug manufacturers, medical equipment manufacturers and biotech companies. Positive news from Celon Pharma S.A. regarding their schizophrenia drug research has uplifted investor confidence, resulting in a rebound of the WIGmed index. Experts believe this optimism can boost the domestic biotechnology sector, though a significant partnership agreement would be beneficial. Valuations suggest that many biotech companies are undervalued. Polish biotech companies are developing treatments for incurable diseases like leukemia, liver cancer, and multiple sclerosis. This progress highlights the vast potential of #biotech, driving interest and investment. Such achievements increase the chances of partnerships and foreign capital, benefiting both patients and shareholders 🌟 #polishbiotech #biopharma #biotech #innovation #funding #oncology

Do you want to learn more about some of the top biotech companies based in Denmark? 🇩🇰 In recent years, Denmark’s life sciences sector has accelerated its output of high-quality research, as the country was ranked 16th overall for biological sciences-related output in 2022. 🚀 It is also among the fastest-growing nations in Europe for biotech investment, hitting $434 million in 2021. 💰 Check out our latest article as we take a look at 9 biotech companies in Denmark leading innovation in the sector. 👇️ https://lnkd.in/dfcA8RCn #biotechindenmark #lifesciences #innovation #biotechinvestment #danishbiotech #researchanddevelopment #biotechcompanies #bioinnovation Acesion Pharma | Adcendo | Ascendis Pharma | Bavarian Nordic | Genmab | Hoba Therapeutics | IO Biotech | Minervax ApS | Zealand Pharma

Superluminal Medicines, a Boston, MA-based company that uses generative biology, chemistry and machine learning approaches to create medicines, raised $120M in Series A funding. The round was led by RA Capital Management with participation from existing investors Insight Partners, NVentures (NVIDIA’s venture capital arm), and Gaingels. New investors Catalio Capital Management, Eli Lilly and Company, and Cooley LLP joined in the financing, and Diamantis Xylas, MD of Catalio joined the Board of Directors. https://lnkd.in/eDTTgE9f The company intends to use the funds to support the progression of its lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets. Led by CEO Cony D’Cruz, Superluminal Medicines is a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Its platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Its discovery engine is powered by a pharmacokinetic and toxicology in silico prediction capability. The company’s proprietary pipeline validates its platform with initial programs focused on high-value GPCR targets.

Tune in March 7th @10am ET to listen to Genflow Biosciences (LON:GENF) (OTCQB:GENFF) CEO Eric Leire as he talks through his pioneering genetic therapy approach to longevity, with the goal of decelerating the ageing process to mitigate the financial, emotional, and social impacts of a fast-growing ageing global population. Register here: https://bit.ly/3TaWlkL Highlights: ✅ With upcoming clinical trails scheduled to begin in 2025, Genflow Biosciences' is exploring the potential benefits of its lead compound, GF-1002 in treating non-alcoholic steatohepatitis (NASH), the most prevalent chronic liver disease for which there are no effective treatments. ✅ Genflow Bioscience’s lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. ✅ Genflow was awarded 2.89 million Euros in two new grants that will broaden its research pipeline and expand the size of its therapeutic markets over the next three years. ✅ Genflow to undertake key Investigational New Drug (IND)-enabling development activities that will help define the pharmacological and toxicological properties of its lead drug candidate, GF-1002, and its potential benefits for NASH patients. ✅ Initial site selection and QMS framework for clinical readiness, expected by the end of 2025 for its NASH program. #longevity #biotech #slowdownageing #healthierlongerlifes OTC Markets Group